Cardiovascular diseases account for approximately 50% of the mortality in patients with end-stage renal disease (ESRD) undergoing hemodialysis (HD) (1, 2) . The incidence of cardiac death is 5-10 times higher in these patients than in the age-matched general population (3) .
The increased incidence of atherosclerotic cardiovascular disease in ESRD patients is probably the result of a high prevalence of both traditional and nontraditional, or better modifiable and non modifiable risk factors. Based on the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) study (4) , a large percentage of incident dialysis patients have more traditional risk factors of atherosclerosis such as hypertension, diabetes mellitus, dyslipidemia, left ventricular hypertrophy, and increased age than the normal population.
Infectious and inflammator y complications are nontraditional risk factors that recently have attracted interest in nonrenal patient groups because they repeatedly have been shown to be associated with cardiovascular disease (5) . Nevertheless high C-reactive protein (CRP) levels and a composite risk factor made-up of malnutrition and inflammation have shown to be present in the dialysis population and to correlate with bad outcome and high incidence of comorbidity. Futhermore dialysis patients appear more prone to infection than the general population. Among persistent bacterial infections, Chlamydia pneumoniae, an obligate intracellular pathogen, has been implicated as an additional risk factor for development of atherosclerosis (6, 7) .
Involvement of C. pneumoniae in the pathogenesis of atherosclerosis has been supported by seroepidemiology, identification of the organism within atheromas by immunohistochemistry, and within foam cells by electron microscopy, and direct detection of chlamydial DNA within atheroma by polymerase chain reaction (PCR) (8) (9) (10) (11) (12) (13) .
Although ample clinical data exist to suggest a role for C. pneumoniae in atherosclerosis, how the organism may initiate or promote the disease remains unclear.
Evidence linking C. pneumoniae infection to atherosclerosis thought to contribute directly to cardiovascular disease in dialysis patients has emerged only recently.
There are several studies linking C. pneumoniae antibodies to increased carotid intima-media thickness in pre-dialysis chronic kidney disease (CKD) patients (14), carotid plaque number in HD and continuous ambulatory peritoneal dialysis (CAPD) patients (15) , coronary disease in CAPD patients (16) and more severe coronar y calcifications in childhood-onset CKD patients (17) .
Furthermore, it has been shown that the presence of IgA titres in C. pneumoniae identify peritoneal dialysis (PD) patients at risk of coronary heart disease (CHD) (16, 18, 19) and death (19) . Atherosclerosis is regarded as chronic inflammatory disease that results from complex interactions between a variety of cell types such as endothelial cell, vascular smooth muscle cell, monocyte/macrophage and their soluble mediators. The impor tance of inflammation in the pathogenesis of atherosclerosis is now well known (5) and CRP has been established as an inflammatory marker (20) . In apparently healthy individuals an elevated serum level of CRP is a predictor of long-term risk of myocardial infarction and stroke (20) . In dialysis patients, CRP is markedly increased and is strongly linked to cardiovascular risk (16) so that in recent studies raised CRP was a powerful predictor of not only mor tality in general but of cardiovascular death in HD patients (16, (21) (22) (23) . On the other hand, the dialysis procedure is a continuous inflammatory stimulus. Uremia and bio-incompatible renal replacement therapies result in enhanced oxidant stress, the production of complement fragments, and cytokines. In patients on long-term hemodialysis therapy, elevated CRP levels are probably caused by the induction of the inflammatory activity of the dialyzer membrane, the dialysate buffer or contamination of dialysate with bacterial components (24) .
Numerous studies have suggested an association of elevated CRP and C. pneumoniae antibodies with carotid plaque number, coronary calcifications, and cardiovascular death in dialysis patients (15-17, 25, 26) .
Chronic and persistent C. pneumoniae infection might be associated with chronic inflammation in HD patients because the bacterium is capable of inducing the production of adhesion molecules and pro-inflammatory cytokines such as interleukin (IL)-1, IL-6 and tumor necrosis factor(TNF)-α (27) that have proven to be predictors of atherosclerotic cardiovascular disease and outcome in dialysis patients (22) .
Tsirpanlis et al (28) showed that C. pneumoniae DNA in PBMC was associated to IL-1 and vascular cell adhesion molecule (VCAM)-1 in HD patients suggesting that C. pneumoniae in circulating monocytes have a central role in the inflammatory atherogenous process. Another finding of Tsirpanlis's study (28) is that C. pneumoniae infection and the use of synthetic membranes were significant predictors for IL-1 levels in dialysis patients.
More recently, investigators have suggested that persistent chlamydial infection might accelerate the atherogenic process by stimulating IL-6 production because a significant association was found between IL-6, the severity of carotid atherosclerosis and IgA antibodies to C. pneumoniae in HD and ESRD patients (29, 30) .
With regard to TNF-α, a statistically significant association between C. pneumoniae serology and elevated levels of TNF-α was observed in CHD patients (31) whereas several authors failed to demonstrate such a relationship in dialysis patients (28, 29) . The role of TNF-α, hence, may be less important in these patients.
Serological studies have revealed several important aspects of the role of C. pneumoniae in dialysis patients but there was a great deal of heterogeneity among these studies in terms of the serologic test and criteria used for seropositivity. In addition, interpretation of serologic results is problematic, since a wide segment of the population has preexisting IgG antibodies anti-C. pneumoniae from previous exposure(s) and it is difficult to precisely differentiate between a chronic, active infection or a past exposure (32) . Lastly, serological tests do not appear suitable for predicting a vascular C. pneumoniae infection because there is poor correlation between C. pneumoniae antibodies and the presence of C. pneumoniae DNA.
Recently several studies have shown the presence of C. pneumoniae DNA in peripheral blood mononuclear cells (PBMC) of both blood donors and patients with atherosclerotic cardiovascular disease suggesting that detection of C. pneumoniae DNA in PBMC may be a valid surrogate marker to identify individual risk for endovascular chlamydial infection (33) (34) (35) . In addition, in a previous study we have demonstrated that the presence of C. pneumoniae DNA in PBMC may be associated with symptomatic carotid atherosclerotic disease (36) . Similarly, in a study on dialysis patients an association was found between the presence of C. pneumoniae DNA in PBMC and coronary or cerebrovascular or peripheral vascular disease (37) . Therefore, the detection of chlamydial DNA by PBMC-based PCR seems to be a firstchoice method to evaluate the role of C. pneumoniae in dialysis patients.
Only a few studies have been done on this topic. Iliescu et al (38) found the presence of C. pneumoniae DNA, in PBMC, in 60% of peritoneal dialysis patients; Muller et al reported a more frequent detection of the C. pneumoniae genome in PBMC in dialysis patients (16.3%) than healthy subjects (8.5%) (39) and Tsirpanlis et al (37) showed the presence of C. pneumoniae DNA, in PBMC, in 6.9% of hemodialysis patients.
The differences in prevalence of C. pneumoniae DNA reported by Iliescu et al (38) , Muller et al (39) and Tsirpanlis et al (37) show that standardization of PCR methods for the detection of C. pneumoniae is needed. Indeed, different volumes of blood collected, DNA extraction procedures, primers, PCR set-up and methods of product visualization were used.
In addition to methodological standardization efforts, we believe that development of a PBMC-based real-time PCR may be a rapid diagnostic approach to characterize an active C. pneumoniae vascular infection in dialysis patients at high risk for atherosclerotic cardiovascular disease.
In an earlier study on patients with atherosclerotic carotid disease, we presented evidence that PBMC-based real-time PCR may be a useful tool for identifying subjects carryng C. pneumoniae, even at a low concentration, in the circulation or in the vascular wall as well. Indeed we used a real-time PCR based on C. pneumoniae PstI species-specific fragment, highly sensitive and reproducible (from 10 6 to 25 C. pneumoniae genomic equivalent) for detection and quantification of C. pneumoniae DNA in PBMC specimens (40) .
Consequently in dialysis patients, PBMC-based realtime PCR may be a specific indicator of current infection and may be used as a marker for assessing the microbiological efficacy of anti-chlamydial therapy in clinical intervention trials.
In conclusion, we believe that the results of intervention trials with a large number of patients and longer duration of anti-chlamydial antibiotic therapy may help to clarify the etiopathogenic role of C. pneumoniae in dialysis patients at high risk for atherosclerotic cardiovascular disease.
